The Science

What the research actually shows.

ORYGN's triGLP is built on ProGo®, a salmon-derived bioactive peptide from Hofseth BioCare (Norway). Rather than repeat marketing language, here's what's actually been published and clinically tested — with real numbers and sources.

Study 01 · Protein Uptake

Faster than whey, on measured leucine levels

ProGo® is a highly hydrolysed protein — 97% pure, broken into small peptides that absorb quickly. In a randomized, double-blind, cross-over trial in healthy young men, ProGo® reached peak blood leucine concentration 15 minutes faster than whey protein. Leucine is the amino acid most closely tied to muscle protein synthesis and to the biological signals involved in feeling full after eating. A separate digestion-simulation study found ProGo® made 67% of its nitrogen available for absorption within two hours — higher than hydrolysed whey protein or whey protein isolate.

Sources: Raastad, Vagle & Framroze (2017), Nutr Food Technol Open Access; Framroze et al. (2014), Functional Foods in Health and Disease.

Study 02 · Weight Management

A measured 5.9% BMI reduction over 42 days

In a 2016 placebo-controlled trial, 48 overweight adults were split into two groups: one took ProGo® (16g/day), the other took whey protein isolate, both alongside their normal diet and exercise routine. After 42 days, 19 of 23 subjects in the ProGo® group showed a significant BMI decrease, averaging 5.9% — roughly 4kg for someone weighing 75kg. The whey protein comparison group saw a small (non-significant) weight gain of 1.6% over the same period. Researchers also observed favorable shifts in metabolism-related biomarkers (adiponectin, lipoprotein lipase, bile acid, and interleukin-6) in the ProGo® group.

Source: Framroze, Vekariya & Swaroop (2016), J Obes Weight Loss Ther 6:296.

Study 03 · Iron & Energy

140% increase in serum ferritin

A separate placebo-controlled trial in iron-deficient adults gave subjects 16g/day of ProGo®. Within 42 days, serum ferritin rose by 140% and haemoglobin by 15%, alongside reported improvements in alertness and energy — without the gastrointestinal side effects (nausea, constipation) common with standard iron supplements. This trial is the basis for ProGo®'s FDA structure/function claims around healthy iron levels and energy utilisation.

Source: Framroze, Vekariya & Swaroop (2015), J Nutr Food Sci 5:379-382.

Study 04 · Glucose Metabolism

Blocking the enzyme that breaks down insulin signals

Researchers at Norway's Nofima Research Institute tested ProGo® in vitro for DPP-IV inhibition — DPP-IV is an enzyme that breaks down the body's own insulin-regulating hormones. Low-molecular-weight peptide fractions of ProGo® showed potent DPP-IV inhibition and direct glucose uptake, with the smallest peptide fractions retaining their effect even at high dilution.

Source: Bjerknes, Wubshet, Rønning, et al. (2024), Marine Drugs 22, 151. Peer-reviewed.

Study 05 · Gut Health

Faster gut recovery in a controlled animal study

In a Stanford-affiliated study, mice with chemically-induced colitis were treated with either water, a collagen peptide, or ProGo®'s soluble protein hydrolysate. The ProGo® group showed significantly better recovery — preserved gut structure, reduced inflammation, and increased antioxidant gene activity — while the collagen peptide group showed no meaningful benefit over water, suggesting a specific bioactive effect rather than generic nutrition.

Source: Wei, Tao, Xu, et al. (2022), Biomolecules 12, 1287. Peer-reviewed.

Preliminary · Laboratory Data

Lab testing on GLP-1, GLP-2 & GIP receptor activity

In a dish, not in the body: contract lab testing (a fluorescent biosensor assay) found that ProGo® activated GLP-1, GLP-2, and GIP receptors in a dose-dependent way — for example, roughly doubling GLP-1 receptor signal at 1mg/ml compared to control. This is real laboratory evidence for a plausible mechanism, but it's an in vitro receptor assay, not a measurement of hormone levels or effects in an actual person, and it hasn't yet been published in a peer-reviewed journal. We think the clinical trial data above (BMI, glucose, iron) is the stronger evidence — this section is here for anyone who wants the mechanistic detail behind it.

Where triGLP Fits

A bioactive peptide, not a hormone injection.

triGLP contains ProGo®, a fish-derived bioactive peptide developed by Hofseth BioCare (Norway) over more than a decade of research, with real regulatory recognition:

FDA · United States

NDI Status

New Dietary Ingredient recognition, confirming safety for use in dietary supplements.

FDA · United States

13 Structure/Function Claims

Claim notices the FDA did not oppose within its statutory review window.

Health Canada

4 Qualified Health Claims

Including recognition related to iron absorption, following formal scientific review.

Important distinction: these are ingredient-level regulatory recognitions for a dietary supplement, not FDA approval of triGLP as a drug, and not a claim that it works the same way as, or as a substitute for, prescription GLP-1 medication. Supplements are regulated differently from prescription drugs — always talk to your doctor about what's right for you, especially if you're currently on or considering a prescription GLP-1 therapy.

Curious What's In It

See triGLP & IGNYT full ingredient panel and servings.

Shop →